Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo

European Journal of Medicinal Chemistry

Volumn 103, Issue , 2015, Pages 191-209

  Caraballo, Rémi ^a   Larsson, Mikael ^a   Nilsson, Stefan K ^a   Ericsson, Madelene ^a   Qian, Weixing ^a   Tran, Nam Phuong Nguyen ^a   Kindahl, Tomas ^a   Svensson, Richard ^b   Saar, Valeria ^a   Artursson, Per ^b   Olivecrona, Gunilla ^a   Enquist, Per Anders ^a   Elofsson, Mikael ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

Agonist; Lipoprotein lipase; LPL; Structureeactivity relationship; Triglyceride

Indexed keywords

LIPOPROTEIN LIPASE ACTIVATOR; PHTHALIMIDE DERIVATIVE; TRIACYLGLYCEROL; LIPOPROTEIN LIPASE; N-PHENYLPHTHALIMIDE;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IN VIVO STUDY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CACO 2 CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DESIGN; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM;

ANIMALS; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIPOPROTEIN LIPASE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; PHTHALIMIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGLYCERIDES;

EID: 84941116388     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.08.058     Document Type: Article

References (50)

1. M. Langlois, Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing, Clin. Chem. Lab. Med. CCLM/FESCC 50 (2011) 1169-1181.
2. U. Khot, M. Khot, C. Bajzer, S. Sapp, E. Ohman, S. Brener, S. Ellis, A. Lincoff, E. Topol, Prevalence of conventional risk factors in patients with coronary heart disease, J. Am. Med. Assoc. 290 (2003) 898-904.
3. P. Jousilahti, E. Vartiainen, J. Tuomilehto, P. Puska, Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland, Circulation 99 (1999).
4. E. Barrett-Connor, K. Khaw, Family history of heart attack as an independent predictor of death due to cardiovascular disease, Circulation 69 (1984).
5. H.B. Hubert, M. Feinleib, P.M. McNamara, W.P. Castelli, Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study, Circulation 67 (1983).
6. W. Kannel, D. McGee, Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study, Diabetes Care 2 (1979) 120-126.
7. P.W.F. Wilson, R.B.D. Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel, Prediction of coronary heart disease using risk factor categories, Circulation 97 (1998).
8. P. Cullen, Evidence that triglycerides are an independent coronary heart disease risk factor, Am. J. Cardiol. 86 (2000) 943-949.
9. A. Boullart, J. de Graaf, A. Stalenhoef, Serum triglycerides and risk of cardiovascular disease, Biochim. Biophys. Acta 1821 (2012) 867-875.
10. G. Yuan, K. Al-Shali, R. Hegele, Hypertriglyceridemia: its etiology, effects and treatment, Can. Med. Assoc. J. 176 (2007) 1113-1120.
11. S.M. Grundy, Hypertriglyceridemia, insulin resistance, and the metabolic syndrome, Am. J. Cardiol. 83 (1999) 25F-29F.
12. H. Wang, R. Eckel, Lipoprotein lipase: from gene to obesity, Am. J. Physiol. A 297 (2009) E271-E288.
13. G. Olivecrona, T. Olivecrona, Triglyceride lipases and atherosclerosis, Curr. Opin. Lipidol. 21 (2010) 409-415.
14. S.G. Young, R. Zechner, Biochemistry and pathophysiology of intravascular and intracellular lipolysis, Genes Dev. 27 (2013) 459-484.
15. W. Dijk, S. Kersten, Regulation of lipoprotein lipase by Angptl4, Trends Endocrinol. Metab. 25 (2014) 146-155.
16. C. Li, Genetics and regulation of angiopoietin-like proteins 3 and 4, Curr. Opin. Lipidol. 17 (2006) 152-156.
17. T. Shimizugawa, M. Ono, M. Shimamura, K. Yoshida, Y. Ando, R. Koishi, K. Ueda, T. Inaba, H. Minekura, T. Kohama, H. Furukawa, ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase, J. Biol. Chem. 277 (2002) 33742-33748.
18. V. Sukonina, A. Lookene, T. Olivecrona, G. Olivecrona, Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 17450-17455.
19. C.T. Johansen, S. Kathiresan, R.A. Hegele, Thematic review series: genetics of human lipid diseases: genetic determinants of plasma triglycerides, J. Lipid. Res. 52 (2011) 189-206.
20. L. Berglund, J.D. Brunzell, A.C. Goldberg, I.J. Goldberg, F. Sacks, M.H. Murad, A.F.H. Stalenhoef, Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline, J. Clin. Endocrinol. Metab. 97 (2012) 2969-2989.
21. M. Larsson, R. Caraballo, M. Ericsson, A. Lookene, P.-A. Enquist, M. Elofsson, S.K. Nilsson, G. Olivecrona, Identification of a small molecule that stabilizes lipoprotein lipase in vitro and lowers triglycerides in vivo, Biochem. Biophys. Res. Commun. 450 (2014) 1063-1069.
22. M. Esteves, I. Fragiadaki, R. Lopes, E. Scoulica, M. Cruz, Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents, Bioorg. Med. Chem. 18 (2010) 274-281.
23. C. Suoding, H.-M. Fernando, R. Ren-e, Scope and applications of "active and latent" thioglycosyl donors. Part 4, J. Carbohydr. Chem. 17 (1998).
24. A. Eastwood, A. Blum, N. Zacharias, D. Dougherty, A selenide-based approach to photochemical cleavage of peptide and protein backbones at engineered backbone esters, J. Org. Chem. 74 (2009) 9241-9244.
25. E.J. Carcache de-Blanco, B. Pandit, Z. Hu, J. Shi, A. Lewis, P.-K. Li, Inhibitors of NF-kappaB derived from thalidomide, Bioorg. Med. Chem. Lett. 17 (2007) 6031-6035.
26. N. Hashimoto, T. Aoyama, T. Shioiri, New methods and reagents in organic synthesis. 0.14. A simple efficient preparation of methyl-esters with trimethylsilyldiazomethane (TMSCHN2) and its application to gaschromatographic analysis of fatty acids, Chem. Pharm. Bull. 29 (1981) 1475-1478.
27. P. Zhichkin, L. Peterson, C. Beer, W. Rennells, The use of formamidine protection for the derivatization of aminobenzoic acids, J. Org. Chem. 73 (2008) 8954-8959.
28. B. Fors, P. Krattiger, E. Strieter, S. Buchwald, Water-mediated catalyst preactivation: an efficient protocol for CeN cross-coupling reactions, Org. Lett. 10 (2008) 3505-3508.
29. F. Kwong, A. Klapars, S. Buchwald, Copper-catalyzed coupling of alkylamines and aryl iodides: an efficient system even in an air atmosphere, Org. Lett. 4 (2002) 581-584.
30. J.M. Chapman Jr., P.J. Voorstad, G.H. Cocolas, I.H. Hall, Hypolipidemic activity of phthalimide derivatives. 2. N-Phenylphthalimide and derivatives, J. Med. Chem. 26 (1983) 237-243.
31. T. Woltering, G. Adam, A. Alanine, J.r. Wichmann, F.d.r. Knoflach, V. Mutel, S. Gatti, Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b] [1,4]diazepin-2-one derivatives: new potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1, Bioorg. Med. Chem. Lett. 17 (2007) 6811-6815.
32. P.H. Fries, D. Imbert, Parallel NMR based on solution magnetic-susceptibility differences. Application to isotopic effects on self-diffusion, J. Chem. Eng. Data 55 (2010) 2048-2054.
33. A. Klapars, S. Buchwald, Cooper-catalyzed halogen exchange in aryl halides: an aromatic Finkelstein reaction, J. Am. Chem. Soc. 124 (2002) 14844-14845.
34. F. Bellina, C. Calandri, S. Cauteruccio, R. Rossi, Efficient and highly regioselective direct C-2 arylation of azoles, including free (NH)-imidazole, -benzimidazole and -indole, with aryl halides, Tetrahedron 63 (2007) 1970-1980.
35. Y. Nakamura, S. Inomata, M. Ebine, Y. Manabe, I. Iwakura, M. Ueda, "Clickmade" biaryl-linker improving efficiency in protein labelling for the membrane target protein of a bioactive compound, Org. Biomol. Chem. 9 (2011) 83-85.
36. S. Harper, B. Pacini, S. Avolio, M. Di Filippo, G. Migliaccio, R. Laufer, R. De Francesco, M. Rowley, F. Narjes, Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase, J. Med. Chem. 48 (2005) 1314-1317.
37. M.R. Kumar, A. Park, N. Park, S. Lee, Consecutive condensation, C-N and N-N bond formation: a copper-catalyzed one-pot three-component synthesis of 2H-indazole, Org. Lett. 13 (2011) 3542-3545.
38. A.D. Burrows, C.G. Frost, M.F. Mahon, C. Richardson, Post-synthetic modification of tagged metal-organic frameworks, Angew. Chem. Int. Ed. 47 (2008) 8482-8486.
39. I. Hubatsch, E.G.E. Ragnarsson, P. Artursson, Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers, Nat. Protoc. 2 (2007) 2111-2119.
40. J.B. Houston, Utility of in-vitro drug-metabolism data in predicting in-vivo metabolic-clearance, Biochem. Pharmacol. 47 (1994) 1469-1479.
41. R.S. Obach, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes, Drug Metab. Dispos. 27 (1999) 1350-1359.
42. P. Matsson, C.A.S. Bergström, N. Nagahara, S. Tavelin, U. Norinder, P. Artursson, Exploring the role of different drug transport routes in permeability screening, J. Med. Chem. 48 (2005) 604-613.
43. W. Yin, K. Tsutsumi, Lipoprotein lipase activator NO-1886, Cardiovasc. Drug Rev. 21 (2003) 133-142.
44. K. Tsutsumi, Y. Inoue, A. Shima, K. Iwasaki, M. Kawamura, T. Murase, The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term adminstration inhibits atherogenises in the coronary arteries of rats with experimental atherosclerosis, J. Clin. Invest. 92 (1993) 411-417.
45. G. Shattat, R. Al-Qirim, Y. Al-Hiari, G. Sheikha, T. Al-Qirim, W. El-Huneidi, M. Shahwan, Synthesis and anti-hyperlipidemic: evaluation of N-(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats, Molecules 15 (2010) 5840-5849.
46. W.J. Geldenhuys, D. Aring, P. Sadan, A novel lipoprotein lipase (LPL) agonist rescues the enzyme from inhibition by angiopoietin-like 4 (ANGPTL4), Bioorg. Med. Chem. Lett. 24 (2014) 2163-2167.
47. J.Y. Chang, Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases, Curr. Opin. Investig. Drugs 6 (2005) 994-1001.
48. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, J.-C. Fruchart, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation 98 (1998) 2088-2093.
49. M.M. Aye, E.S. Kilpatrick, P. Afolabi, S.A. Wootton, A.S. Rigby, A.M. Coady, D.D. Sandeman, S.L. Atkin, Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome, Diabetes Obes. Metab. 16 (2014) 545-552.
50. B.Y. Feng, B.K. Shoichet, A detergent-based assay for the detection of promiscuous inhibitors, Nat. Protoc. 1 (2006) 550-553.